ネラチニブ(698387-09-6)

ChemicalBook Optimization Suppliers
名前: Hubei Haiyue Biotechnology Co., Ltd  Gold
電話番号: 15926453367
電子メール: haiyue1682022@163.com
名前: Shanghai jing Hao pharmaceutical technology co., LTD  Gold
電話番号: 021-68900963 15618693615
電子メール: sales@jinghaopharma.com
名前: Shanghai Boyle Chemical Co., Ltd.  
電話番号:
電子メール: sales@boylechem.com
名前: J & K SCIENTIFIC LTD.  
電話番号: 010-82848833 400-666-7788
電子メール: jkinfo@jkchemical.com
名前: Chembest Research Laboratories Limited  
電話番号: 021-20908456
電子メール: sales@BioChemBest.com
ネラチニブ 製品概要
化学名:ネラチニブ
英語化学名:Neratinib
别名:Neratinib(HKI-272);(2E)-N-[4-[[3-chloro-4-(2-pyridinylMethoxy)phenyl]aMino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(diMethylaMino)-2-butenaMide;neratinib;(E)-N-[4-[3-Chloro-4-[(2-pyridinyl)methoxy]anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide;N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide;Unii-jjh94R3pwb;(2e)-n-(4-((3-chloro-4-((pyridin-2-yl)Methoxy)phenyl)aMino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(diMethylaMino)but-2-enaMide neratinib;HKI-272 Neratinib
CAS番号:698387-09-6
分子式:C30H29ClN6O3
分子量:557.04
EINECS:811-237-1
カテゴリ情報:Inhibitors;Anti-cancer & immunity;Antineoplastic;API
Mol File:698387-09-6.mol
ネラチニブ
ネラチニブ 物理性質
融点 185-187°C
沸点 757.0±60.0 °C(Predicted)
比重(密度) 1.33
貯蔵温度 Refrigerator
溶解性Chloroform (Slightly), DMSO (Slightly, Heated, Sonicated), Methanol (Slightly, Heated)
外見 Off-white solid.
酸解離定数(Pka)12.37±0.43(Predicted)
Pale Yellow to Yellow
安全性情報
HSコード 29334900
MSDS Information
ネラチニブ Usage And Synthesis
効能抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
説明The receptor tyrosine kinase HER2 (ErbB2) is a key component of epidermal growth factor receptor complexes that are known to have central roles in cell proliferation and cancer. Neratinib is an orally active, irreversible inhibitor of the HER2 kinase (IC50 = 59 nM). It also potently inhibits several mutants of HER2 and shows 10-fold or greater selectivity over a wide variety of other kinases. As an irreversible inhibitor, neratinib may circumvent acquired resistance developed against reversible inhibitors, including gefitinib . Neratinib has been evaluated in clinical trials against cancers characterized by HER2 overexpression or HER2 activating mutations.
使用An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Antitumor agent.
使用Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM, respectively.
定義ChEBI: A quinoline compound having a cyano group at the 3-position, a 3-chloro-4-(2-pyridylmethoxy)anilino group at the 4-position, a 4-dimethylamino-trans-but-2-enamido group at the 6-position, and an ethoxy group at the 7-position.
targetHER2
貯蔵Store at -20°C
Tags:698387-09-6